FDA
-
-
-
-
-
-
-
Edgewise Therapeutics sells sevasemten to Servier for up to $2.65 billion
-
-
-
-
-
-
-
Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026
-
-
-
-
-
-
-
Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers
-
-
-
-
-
-
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
-
-
-
-
-
-
-
RBC Capital Reiterates Outperform Rating on Edgewise Therapeutics (EWTX)
-
-
-
-
-
-
-
Biopharma 2025 Preview: 'Piper Sandler Sees Lots of Upside Opportunity'
-
-
-
-
-
-
-
Edgewise Therapeutics Inc. (EWTX) Granted EU Orphan Drug Designations for Sevasemten
-
326,531 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

